---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-23-000025"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:44:17.367741+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# LivaNova completes enrollment of 500th unipolar patient in RECOVER depression trial

## Summary
- Independent committee advised enrollment to continue from 475 to 500 unipolar patients per protocol.
- 500th unipolar patient randomized on March 23, 2023; final analysis after 12-month follow-up data.
- Trial evaluates Vagus Nerve Stimulation for difficult-to-treat depression; results to be published.

## SEC filing metadata
- accession: 0001639691-23-000025
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000025/0001639691-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000025/livn-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-23-000025
- JSON: https://secwatch.observer/filing/0001639691-23-000025.json
- Plain text: https://secwatch.observer/filing/0001639691-23-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.